HC Wainwright Issues Positive Forecast for uniQure Earnings

Key Points

• HC Wainwright has raised its FY2029 earnings per share estimate for uniQure to $20.48, maintaining a "Buy" rating and a $110.00 price target, despite a current consensus estimate of a loss of ($3.75) per share.
• Several analysts have recently increased their target prices for uniQure, with forecasts ranging from $68.00 to $110.00, reflecting optimistic market sentiment towards the company's future performance.
• In the past 90 days, insiders at uniQure have sold a total of 244,316 shares, amounting to over $10 million, with significant sales by both the CFO and CEO, indicating potential shifts in confidence among company leadership.

uniQure N.V. (NASDAQ:QURE - Free Report) - HC Wainwright raised their FY2029 earnings per share estimates for shares of uniQure in a note issued to investors on Monday, October 6th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn $20.48 per share for the year, up from their previous estimate of $20.36. HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million.

Several other equities analysts also recently commented on the stock. Leerink Partners upped their price target on shares of uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a report on Wednesday, September 24th. Chardan Capital boosted their target price on uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a research report on Thursday, September 25th. UBS Group set a $95.00 target price on uniQure in a research note on Thursday, September 25th. Royal Bank Of Canada reissued an "outperform" rating on shares of uniQure in a research note on Wednesday, September 24th. Finally, Wells Fargo & Company boosted their price objective on uniQure from $65.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $71.75.

uniQure Trading Down 3.7%

Shares of QURE opened at $52.91 on Tuesday. The company's fifty day simple moving average is $22.35 and its 200-day simple moving average is $16.67. The company has a market cap of $2.90 billion, a P/E ratio of -13.50 and a beta of 0.56. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a twelve month low of $5.03 and a twelve month high of $60.70.

Insider Buying and Selling at uniQure

In other news, CFO Christian Klemt sold 15,000 shares of the firm's stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer owned 217,730 shares in the company, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares of the company's stock, valued at $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock worth $10,328,181 over the last 90 days. 4.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new stake in uniQure during the 2nd quarter worth approximately $29,217,000. Vestal Point Capital LP raised its holdings in shares of uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after buying an additional 1,767,572 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after buying an additional 1,491,486 shares during the period. Sofinnova Investments Inc. grew its holdings in shares of uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock valued at $21,723,000 after buying an additional 1,012,585 shares during the last quarter. Finally, Aberdeen Group plc increased its position in shares of uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after acquiring an additional 706,216 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.